Plasma Fractionation Market Growth Analysis, Technological Developments, and Forecast 2032
Plasma Fractionation Market Growth Analysis, Technological Developments, and Forecast 2032
The plasma fractionation market involves the separation of plasma components to produce life-saving therapies used in treating immune deficiencies, bleeding disorders, and other medical conditions. Key plasma-derived products include immunoglobulins, albumin, coagulation factors, and protease inhibitors. These products play a crucial role in immunology, hematology, neurology, and critical care medicine. Market growth is driven by the increasing prevalence of chronic and rare diseases, rising demand for plasma-derived therapies, and advancements in fractionation technology that enhance yield and purity. Additionally, the growing use of immunoglobulins in autoimmune and inflammatory diseases is a major factor fueling demand.
The global plasma fractionation market size was valued at USD 37.31 billion in 2024 and is projected to grow from USD 40.27 billion in 2025 to USD 72.45 billion by 2032, exhibiting a CAGR of 8.75% during the forecast period. The market growth is driven by the increasing prevalence of chronic diseases, advancements in plasma-derived therapies, and the rising demand for immunoglobulins and coagulation factors across the globe. North America dominated the plasma fractionation market with a market share of 56.18% in 2024, attributed to its well-established healthcare infrastructure, strong donor base, advanced production facilities, and the presence of major players such as CSL Behring, Grifols, Takeda Pharmaceutical, and Kedrion Biopharma.
The Fortune Business Insights report provides a detailed overview of the plasma fractionation industry, covering market size, share, segmentation, regional insights, competitive landscape, product pipeline, and post-COVID recovery analysis. The study offers a holistic view of key trends shaping the global plasma fractionation landscape.
CSL Behring (U.S.)
Grifols, S.A. (Spain)
Takeda Pharmaceutical Company Limited (Japan)
Kedrion S.p.A (Italy)
Octapharma (Switzerland)
ADMA Biologics, Inc. (U.S.)
Sartorius AG (Germany)
LFB (France)
These players drive the market through strategic initiatives such as expanding plasma-collection networks, investing in R&D, launching new therapeutics, and leveraging regulatory approvals.
Rising prevalence of immune deficiency, bleeding, and chronic disorders that require plasma-derived therapies.
Advancements in plasma fractionation processes improving yield, purity, and cost-effectiveness.
Expansion of plasma donation centers and collection networks, especially in North America.
Growing demand for biologics and plasma-based products across multiple therapeutic areas.
Stringent regulatory requirements for plasma collection and safety increase cost and delay approvals.
High production and infrastructure costs limit access in developing economies.
Supply chain constraints and plasma donor shortages affect consistent production.
Emergence of recombinant alternatives may reduce dependence on plasma-derived products.
The competitive landscape is dominated by multinational leaders such as CSL Behring, Grifols, and Takeda, who together hold a significant market share. These companies are focusing on mergers and acquisitions, facility expansion, and collaborations to strengthen their portfolios. Smaller and emerging players are entering niche therapeutic segments to gain market traction.
Albumin
Immunoglobulin (Intravenous Immunoglobulin - IVIG, Subcutaneous Immunoglobulin - SCIG)
Coagulation Factors (Factor VIII, Factor IX, Prothrombin Complex Concentrates, Fibrinogen Concentrates)
Protease Inhibitors
Others
Immunology & Neurology
Hematology
Critical Care
Pulmonology
Others
Hospitals & Clinics
Clinical Research Laboratories
Others
Explore the full research report with detailed insights and TOC: https://www.fortunebusinessinsights.com/industry-reports/plasma-fractionation-market-101614
North America dominated the global market in 2024 with a share of over 56%, valued at USD 20.96 billion. The region’s dominance is attributed to advanced healthcare infrastructure, the presence of major market players, and strong regulatory frameworks supporting plasma collection and use.
Europe ranked as the second-largest market, expected to reach approximately USD 8.50 billion in 2025, growing at a steady CAGR of 7.8%. Major countries contributing to the region’s growth include Germany, the U.K., and France, supported by increasing awareness of plasma-based therapies and favorable reimbursement policies.
Asia Pacific is projected to register the fastest growth rate through 2032, driven by expanding healthcare access, rising chronic disease burden, and growing plasma donation programs in China, Japan, and India. The regional market is anticipated to reach nearly USD 7.8 billion in 2025.
The plasma fractionation market is set for substantial expansion in the coming decade. From USD 40.27 billion in 2025, the market is projected to reach USD 72.45 billion by 2032, driven by growing adoption of immunoglobulin products, improved plasma collection infrastructure, and expansion into emerging regions. Innovations in manufacturing and fractionation technologies are also expected to improve productivity and safety standards.
Key growth opportunities lie in immunoglobulin therapies for autoimmune and neurological disorders, expansion of albumin use in critical care, and integration of advanced purification systems. Strategic collaborations and digitalization across plasma supply chains will further enhance efficiency and transparency.
The plasma fractionation market continues to evolve as a vital segment of the global biopharmaceutical industry. With a growing demand for life-saving plasma-derived therapies, technological innovations, and expanding collection networks, the industry is positioned for strong and sustainable growth. Despite regulatory challenges and high production costs, the market outlook remains positive, supported by strategic investments and collaborative advancements by leading players.
About Us:
Fortune Business Insights provides expert corporate analysis and accurate data, enabling businesses of all sizes to make timely decisions. We offer customized solutions tailored to each client’s needs, helping them address unique challenges. Our goal is to empower clients with holistic market intelligence and offer granular insights into the market they operate in.
At Fortune Business Insights, we aim to highlight growth opportunities for our clients, offering insights and recommendations that help them navigate technological and market changes. Our consulting services are designed to help companies uncover hidden opportunities and address competitive challenges.
Contact us:
Fortune Business Insights™ Pvt.
Phone: USA: +1 833 909 2966 (Toll-Free),
United Kingdom: +44 808 502 0280 (Toll-Free),
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com